May 2 2006, 8:00 AM EST
News source: Business Wire
Biovail Pharmaceuticals, Inc. to Promote Zoladex(R) 3.6mg to Obstetricians/Gynecologists for Endometriosis IndicationBiovail Corporation (NYSE:BVF)(TSX:BVF) today announced that Biovail Pharmaceuticals, Inc. (BPI), the Company's wholly owned U.S. subsidiary, and AstraZeneca Pharmaceuticals LP have entered into an agreement for which BPI's specialty sales force will promote Zoladex(R) 3.6mg (goserelin acetate implant) to obstetricians and gynecologists for the treatment of endometriosis in the United States and Puerto Rico.
AstraZeneca will continue to manufacture and supply all quantities of Zoladex(R)
Biovail Chief Executive Officer Dr. Douglas Squires said the opportunity to promote the 3.6mg formulation of Zoladex(R) to OB/GYNs will further enable the Company to build its portfolio of products to promote to the women's health-care market.
"Biovail will leverage its expertise and relationships with women's health-care practitioners in the United States to proactively position the therapeutic benefits of Zoladex(R) 3.6mg as an important treatment to females who suffer from endometriosis," said Dr. Squires. "This strategic alliance with AstraZeneca for Zoladex(R) is a reaffirmation of Biovail's ability to enter into, and provide value to, Tier 1 pharmaceutical companies."
Lisa Schoenberg, Vice-President, Specialty Care, at AstraZeneca Pharmaceuticals LP, says that the company is excited about this partnership with Biovail.
"After giving careful consideration to several women's health companies, we feel that a strategic partnership with Biovail will provide an opportunity to bring significant benefits to women who suffer from endometriosis," says Ms. Schoenberg. "Biovail's sales organization has a proven track record, and has built a solid reputation with OB/GYNs, and women's health-care practitioners."
Biovail's 85-member specialty sales force currently promotes Zovirax(R) Cream and Zovirax(R) Ointment, leading topical anti-viral treatments for genital herpes and cold sores, to specialists and selected primary-care physicians in the U.S. More recently, Biovail entered into an agreement to provide promotion services for extended-release and immediate-release formulations of tramadol - Ultram(R) ER and Ultram(R) ODT respectively - to women's health-care practitioners. Ultram(R) ER was launched in February; Biovail and OMI anticipate the launch of Ultram(R) ODT later in mid-2006.
About Zoladex(R)
Zoladex 3.6mg is indicated for the management of endometriosis, including pain relief and reduction of endometriatic lesions for the duration of therapy. Experience for the management of endometriosis has been limited to women 18 years of age and older treated for six months.
Zoladex 3.6mg competes in the $934.8-million GnRH (gonadotropin releasing hormone) agonist analogs market. Statistics from IMS Health for the 12 months ended December 31, 2005, show that almost 338,000 prescriptions were written for GnRH analogs.
About Endometriosis
Endometriosis is a painful, chronic disease that affects over 5.5 million women in the United States and Canada, and millions more worldwide, according to the U.S.-based Endometriosis Association. It occurs when tissue similar to that which lines the uterus (tissue called the endometrium) is found outside the uterus - usually in the abdomen on the ovaries, fallopian tubes, and ligaments that support the uterus; the area between the vagina and rectum; the outer surface of the uterus; and the lining of the pelvic cavity.
This misplaced tissue develops into growths or lesions that respond to the menstrual cycle in the same way that the tissue of the uterine lining does: each month the tissue builds up, breaks down, and sheds. Menstrual blood flows from the uterus and out of the body through the vagina, but the blood and tissue shed from endometri
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All